| SC 13G/A | 2020-02-14 | ARK Investment Management LLC | Arcturus Therapeutics Ltd. | 1,383,756 | 9.1% | EDGAR |
| SC 13G/A | 2019-02-20 | Brosh Capital L.P. | Arcturus Therapeutics Ltd. | 391,754 | 3.7% | EDGAR |
| SC 13G | 2019-02-14 | ARK Investment Management LLC | Arcturus Therapeutics Ltd. | 815,176 | 7.6% | EDGAR |
| SC 13G/A | 2019-01-25 | FRANKLIN RESOURCES INC | Arcturus Therapeutics Ltd. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2018-11-20 | Payne Joseph E | Arcturus Therapeutics Ltd. | 1,469,097 | 13.7% | EDGAR |
| SC 13G | 2018-06-11 | Brosh Capital Partners L.P. | Arcturus Therapeutics Ltd. | 453,863 | 4.2% | EDGAR |
| SC 13D/A | 2018-05-24 | Sorenson Bradley T. | Arcturus Therapeutics Ltd. | 692,392 | 6.5% | EDGAR |
| SC 13D/A | 2018-05-23 | Payne Joseph E | Arcturus Therapeutics Ltd. | 1,465,097 | 13.7% | EDGAR |
| SC 13D/A | 2018-05-15 | Payne Joseph E | Arcturus Therapeutics Ltd. | 1,465,097 | 13.7% | EDGAR |
| SC 13D/A | 2018-05-02 | Payne Joseph E | Arcturus Therapeutics Ltd. | 1,465,097 | 13.7% | EDGAR |
| SC 13D | 2018-04-30 | Brosh Capital Partners L.P. | Arcturus Therapeutics Ltd. | 453,863 | 4.2% | EDGAR |
| SC 13D/A | 2018-04-23 | Payne Joseph E | Arcturus Therapeutics Ltd. | 1,465,097 | 13.7% | EDGAR |
| SC 13D/A | 2018-04-19 | Payne Joseph E | Arcturus Therapeutics Ltd. | 1,465,097 | 13.7% | EDGAR |
| SC 13D/A | 2018-04-13 | Payne Joseph E | Arcturus Therapeutics Ltd. | 1,465,097 | 13.7% | EDGAR |
| SC 13G | 2018-04-09 | Brosh Capital Partners L.P. | Arcturus Therapeutics Ltd. | 447,053 | 4.2% | EDGAR |
| SC 13D/A | 2018-04-04 | Payne Joseph E | Arcturus Therapeutics Ltd. | 1,465,097 | 13.7% | EDGAR |
| SC 13D | 2018-02-22 | Chivukula Pad | Arcturus Therapeutics Ltd. | 732,548 | 6.9% | EDGAR |
| SC 13D/A | 2018-02-13 | Payne Joseph E | Arcturus Therapeutics Ltd. | 1,465,097 | 13.7% | EDGAR |
| SC 13G/A | 2018-02-13 | BAKER BROS. ADVISORS LP | Arcturus Therapeutics Ltd. | 0 | 0.0% | EDGAR |
| SC 13G | 2018-02-13 | Broadfin Capital, LLC | Arcturus Therapeutics Ltd. | 0 | 0.0% | EDGAR |